Dracen Pharmaceutical
  • About Us
    • Leadership Team
    • Board of Directors
    • Scientific Founders
    • Investors
  • Our Science
    • Our Goal
    • Mechanism of Action
    • Glutamine-Addicted Tumors
  • Pipeline
    • Clinical Trials
  • Publications
    • Papers
    • Posters
    • Presentations
  • News
  • Contact Us
Dracen Pharmaceutical
MENU
  • About Us
    • Leadership Team
    • Board of Directors
    • Scientific Founders
    • Investors
  • Our Science
    • Our Goal
    • Mechanism of Action
    • Glutamine-Addicted Tumors
  • Pipeline
    • Clinical Trials
  • Publications
    • Papers
    • Posters
    • Presentations
  • News
  • Contact Us
MENU
  • About Us
    • Leadership Team
    • Board of Directors
    • Scientific Founders
    • Investors
  • Our Science
    • Our Goal
    • Mechanism of Action
    • Glutamine-Addicted Tumors
  • Pipeline
    • Clinical Trials
  • Publications
    • Papers
    • Posters
    • Presentations
  • News
  • Contact Us

News

November 8, 2019
Dracen Pharmaceuticals announces DRP-104 presentations at the 2019 Society of Immunotherapy of Cancer (SITC) Meeting

Dracen Announces AACR Presentation
April 12, 2018
PDF Version

Dracen Closes Financing to Advance Immunometabolism Pipeline
March 22, 2018
PDF Version

Dracen Licenses Immunometabolism Platform
January 11, 2018
PDF Version

Uncategorized
  • « Hello world!
  • Posters »

About Us   Our Science   Pipeline   Publications   News   

© 2022 Dracen Pharmaceuticals